Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Imaging Studies VI: Voiding Cystourethrography and Cystography

Imaging Studies VI: Voiding Cystourethrography and Cystography

Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Single-event fast neutron time-of-flight spectrometry with a petawatt-laser-driven neutron source.

Nature communications·2026

Same author

Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025

Same author

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

[Less is more: dose de-escalation in early anal cancer-Clinical and functional aspects of quality of life from the PLATO-ACT4 trial].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025

Same author

Reply to the Letter to the Editor by Perez et al. regarding "Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials".

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: 5-year results of the CAO/ARO/AIO-12 trial - a general pairwise comparison.

ESMO open·2025

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

[Radiochemotherapeutic options for bladder cancer].

C Weiss¹, R Sauer, C Rödel

¹Klinik für Strahlentherapie und Onkologie, Universität Frankfurt.

Aktuelle Urologie

|April 2, 2008

Summary

Radiochemotherapy offers an organ-preserving alternative for bladder cancer, with good survival and bladder function rates for muscle-invasive disease. Salvage surgery is an option for non-responders.

Area of Science:

Urology
Oncology

Background:

Radical cystectomy is standard for muscle-invasive bladder cancer.
Organ-preserving approaches like transurethral resection (TUR) and intravesical therapy are recommended for high-risk superficial bladder cancer.

Purpose of the Study:

To review radiochemotherapy options for high-risk T1 or muscle-invasive bladder cancer.
To evaluate these options as alternatives or neoadjuvant therapy before radical surgery.

Main Methods:

Review of radiochemotherapeutic strategies for bladder cancer.
Analysis of recurrence, progression, and survival rates associated with multimodality therapy.

Main Results:

For high-risk T1 bladder cancer, multimodality therapy (TUR, radiation, chemotherapy) shows 30% recurrence and 15% progression rates.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Experiment Videos

Last Updated: Jul 6, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

For muscle-invasive bladder cancer, 5-year survival rates of 50-60% are comparable to cystectomy, with 80% of survivors maintaining bladder function.

Organ-preserving approaches are suitable for early-stage unifocal tumors (T1/T2).

Conclusions:

Radiochemotherapy is a viable organ-preserving option for bladder cancer, offering comparable survival to cystectomy for muscle-invasive disease.
Close multidisciplinary coordination is crucial for optimal outcomes.
Salvage cystectomy is essential for non-responders or recurrences.